Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Clicks: 419
ID: 110503
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Compared with placebo, 35%-40% more patients receiving a full induction course of vedolizumab had sustained clinical remission after 52 weeks of therapy. This result was observed irrespective of TNF antagonist treatment history. Clinical remission at week 14 may therefore be a predictor for sustaine …
Reference Key
bg2019inflammatorysustained Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Feagan BG;Schreiber S;Wolf DC;Axler JL;Kaviya A;James A;Curtis RI;Geransar P;Stallmach A;Ehehalt R;Bokemeyer B;Khalid JM;O'Byrne S;;
Journal inflammatory bowel diseases
Year 2019
DOI
DOI not found
URL
https://www.pubmed.gov/30365009/##supplemental-data
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine prognosis research support non-u.s. gov't adult female male Remission Induction Antibodies Monoclonal follow-up studies pmid:30365009 PMC6499937 doi:10.1093/ibd/izy323 Brian G Feagan Stefan Schreiber Sharon O'Byrne Humanized / therapeutic use* Colitis Ulcerative / drug therapy* Gastrointestinal Agents / therapeutic use* Induction Chemotherapy* Severity of Illness Index*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.